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Introduction: Current medical management of short bowel syndrome (SBS) involves the 
use of lifelong parenteral nutrition (PN). Glucagon-like peptide-2 (GLP-2), an important 
intestinotrophic growth factor has been shown to increase intestinal absorption in SBS through 
augmentation of post-resection intestinal adaptation. This may lead to the reduction of PN 
dependence in patients with SBS.
Areas covered in review: Advancing research of GLP-2 physiology has spurred the growing 
understanding of the diverse effects of GLP-2. The development of the degradation resistant 
GLP-2 analog, teduglutide (GattexTM, NPS Pharmaceuticals, Bedminster, NJ), has allowed its 
exploration as a therapeutic agent in a variety of clinical settings. Recent multicenter, placebo-
controlled studies of GLP-2 in SBS patients demonstrate meaningful reductions in PN require-
ments with good safety profiles. The reparative and immunomodulatory effects of teduglutide 
may also be beneficial in patients with inflammatory bowel disease (IBD). Safety concerns about 
possible carcinogenic properties during long-term use require ongoing evaluation.
Summary: GLP-2 appears to offer a novel adjuvant treatment modality for SBS. Promise for 
its use in other clinical settings like IBD has been shown in small pilot studies.
Keywords: glucagon-like peptide-2, intestinal failure, intestinal adaptation, parenteral 
nutrition
Introduction
Short bowel syndrome (SBS) is defined by a combination of symptoms and signs that 
occur after extensive surgical resection of the intestine. This highly disabling   condition 
is characterized by malabsorption of both fluid and nutrients and, left untreated, can 
lead to dehydration, malnutrition, and weight loss. The term intestinal failure (IF) 
applies when an adequate balance of nutrients and water cannot be maintained without 
dietary support. IF often remains a short-term problem in the postoperative period. 
However, a small number of patients will require long-term parenteral nutrition (PN) 
or, in selected cases, intestinal transplantation. Such patients will typically have less 
than 100 cm of small bowel leading to an end-stoma or less than 50 cm connected to 
a functioning colon. Although PN has revolutionized IF treatment, it has a significant 
impact on quality of life and carries considerable risks, mainly hepatic failure, central 
vein thrombosis, and recurrent sepsis, all of which will reduce life expectancy. Survival 
following intestinal transplantation is still inferior to that of long-term PN due to the 
high incidence of graft rejection and other postoperative complications.1
Soon after surgical resection with resulting loss of   surface area, the intestine 
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of intestinal adaptation occurs through structural (villous cell 
hyperplasia, increased crypt depth, and intestinal dilatation) 
and   functional (increased mucosal enzyme activity and 
reduction of intestinal transit) mechanisms leading to a 
gradual increase in absorptive capacity. This period of 
adaptation is thought to last up to 24 months. Nutritional 
(eg, glutamine) and non-nutritional (eg, growth factors) 
substances have been implicated in promoting this adaptive 
response. In the last decade, most IF research has been 
focused on exploring the potential of these substances as 
supportive IF treatment. However, clinical trials so far have 
not demonstrated reproducible or meaningful clinical benefits 
with the use of glutamine or growth hormone.2–5
Current supportive medical management includes the 
use of agents that reduce secretion (H2 receptor blockers, 
proton pump inhibitors, and octreotide) and motility (codeine, 
opium, lomotil, and loperamide).6 The goal is to reduce the 
total stool output to ,2 L per day. Dietary advice to maximize 
intestinal absorption is highly beneficial but needs to be 
tailored to the anatomy of the residual bowel.
The naturally occurring gut hormone, glucagon-like 
peptide-2 (GLP-2), is a pleiotropic intestinotrophic   hormone 
that enhances digestive and absorptive capacity.7 Recent 
advances in our understanding of the basic science of GLP-2 
have led to its exploration as a potential ‘first in class’ 
therapeutic drug for SBS.
Glucagon-like peptide-2  
and teduglutide
Glucagon-like peptide-2 is a 33-amino acid peptide with 
an estimated molecular mass of 3765.8.8 GLP-2 is derived 
from the post-translational processing of pro-glucagon, a 
large prohormone that is mainly expressed in the pancreas, 
intestine, and brain (Figure 1). In the intestine, biologi-
cally active GLP-21–33 is secreted from enteroendocrine 
L-cells of the ileum and colon in response to nutritional, 
hormonal, and neural stimulation. Human and animal 
studies have revealed that dietary fiber and short-chain 
fatty acids, carbohydrates, and fats are potent stimulators 
of GLP-2 secretion.9
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Figure 1 Proglucagon contains three homologous hormonal sequences, glucagon/GLP-1/GLP-2, and is separated by intervening peptides iP1/iP2. Proglucagon is processed 
differentially in pancreas, intestine, and CNS. 
Abbreviations: CNS, central nervous system; GLP, glucagon-like peptide; GRPP, glicentin-related polypeptide; iP, intervening peptide; MPGF, major proglucagon fragment.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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GLP-2 exerts a wide variety of effects on the gastrointestinal 
tract and is a key mediator of intestinal adaptation.10 In ani-
mal studies, GLP-2 treatment induces mucosal growth in 
the small and large intestine through an increase in crypt 
cell proliferation and a reduction of villous cell apoptosis 
(Figure 2).11,12 This increase in mucosal mass is accompanied 
by enhanced functional absorptive capacity.13 Other GLP-2-
mediated effects include inhibition of gastric emptying and 
acid secretion,14,15 reduction of intestinal permeability,16,17 
anti-inflammatory actions,18 and stimulation of mesenteric 
blood flow.19
Specific G-protein coupled GLP-2 receptors (GLP-2Rs) 
are found in abundance in the proximal small intestine and 
have been demonstrated on enteroendocrine cells,20 enteric 
neurons,19 and subepithelial myofibroblasts.21 The apparent 
lack of GLP-2Rs on the proliferative crypt cells suggests that 
the effects of GLP-2 are mediated through a variety of down-
stream effectors (Figure 3).22 Insulin-like growth factor-1 
appears to be essential for GLP-2-induced intestinal epithe-
lial proliferation,23 and nitric oxide might be a key mediator 
in GLP-2-induced upregulation of intestinal blood flow.19 
Vascular endothelial growth factor and transforming growth 
factor-β have been linked to GLP-2-induced wound repair.24 
The release of vasoactive intestinal peptide (VIP) from enteric 
neurons appears to mediate some of the anti-inflammatory 
effects of GLP-2.25 For further, in-depth discussion into the 
complex interplay of GLP-2 and its downstream mediators 
the authors of this paper recommend a recent review by 
Rowland and Brubaker.26
GLP-2 has a short half-life of approximately 7 minutes 
in humans and undergoes N-terminal truncation by the 
proteolytic enzyme dipeptidyl peptidase IV (DPPIV) to the 
biologically inactive form GLP-2.3–33 Blocking of DPPIV 
degradation, either through glycine substitution in position 2, 
as in teduglutide, or through adjuvant use of DPPIV inhibitors 
extends the use of GLP-2 half-life and confers greater 
biological potency. DPPIV inhibition enhances the intesti-
notrophic effect of GLP-2 in rats and mice.28
AB
Figure 2 Effect of GLP-2 on murine small intestine. Histological appearance of small 
intestine epithelium from control (A) and GLP-2-injected (10 days) (B) mice. 
Reproduced with permission from Drucker et al.11 
© Copyright 1996 National Academy of Sciences, USA. 
Abbreviation: GLP, glucagon-like peptide.
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Figure 3 Proposed model for the indirect mechanisms of GLP-2 action in the 
intestine.  Expression  of  the  GLP-2R  in  intestinal  endocrine  cells  (A),  intestinal 
SEMFs (B), and enteric neurons (C) suggests that GLP-2 acts indirectly to produce 
its diverse actions in the intestine. iGF-i is critical for the ability of GLP-2 to induce 
intestinal  growth  and  activate  crypt  cell  proliferation.  GLP-2-mediated  enteric 
neuronal signaling enhances intestinal blood flow through a mechanism involving 
NO production and has anti-inflammatory actions through VIP. 
Used with permission from Dubé et al, American Journal of Physiology – Endocrinology 
and Metabolism, vol 293; E460–E465, 2007.22 
Abbreviations:  GLP-2,  glucagon-like  peptide-2;  GLP-2R,  glucagon-like  peptide-2 
receptor;  iGF,  insulin-like  growth  factor;  NO,  nitric  oxide;  SEMF,  subepithelial 
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requirements from baseline of more than 20%. The PN 
reductions were made in standardized fashion when the 
urine volume increased to a certain threshold. The increased 
urine production was considered as a surrogate marker for 
increased intestinal wet-weight absorption. The reported 
primary efficacy endpoint of the study, was based on a 
graded response score (GRS) that accounted for both inten-
sity (reduction from baseline of 20%–100%) and duration 
of response (response at weeks 16, 20, and 24). Although no 
statistical significance could be shown for the 0.10 mg/kg/
day dose group, the GRS in the lower 0.05 mg/kg/day dose 
group were significantly better than in the placebo group 
(P = 0.007). Also, a .20% reduction of PN was achieved in 
significantly more patients treated with the 0.05 mg/kg/day 
teduglutide compared with placebo (46% (16/35) vs 6% 
(1/16), P = 0.005).33 The   difference between 0.10 mg/kg/day 
teduglutide and placebo was not significant (25% vs 6.3% 
responders: P = 0.161). Three patients were weaned off 
PN completely (two in the low- and one in the high-dose 
treatment group).
The apparent lack of significant treatment response using 
0.10 mg/kg/day teduglutide is thought to be related to protocol 
restrictions that could not take into account decreased oral 
fluid intake, which occurred significantly more often in the 
high dose patient group, as well as a trend towards higher 
baseline PN requirements and shorter remnant short bowel. 
Post hoc evaluation of the net effect of teduglutide estimates a 
similar efficacy of both treatment doses resulting in increased 
liquid absorption of approximately 700 mL (4.9 L per week), 
which is very much in keeping with the results of the open-
label trials. The investigators also argue that the therapeutic 
benefit of teduglutide might have been underestimated by 
considering PN reduction as isolated endpoints, rather than 
taking into account additional positive effects on hydration 
and renal function. Teduglutide led to a significant increase in 
urine excretion in the low-dose group, and despite a reduced 
oral intake, urine output was maintained in the high-dose 
group. Although energy absorption was not quantified in this 
study, there was a small increase in body weight and lean 
body mass in both treatment groups, despite reduction in PN 
calorie provision.34 Plasma citrulline, a sensitive marker for 
enterocyte mass and function, increased with low- and high-
dose treatment but not with placebo, indicating a teduglutide-
related intestinotrophic effect. Accordingly, increased villous 
height was documented in both treatment groups.
The aforementioned study was followed up with a 
28-week extension study that enrolled 65 patients that 
had completed the initial trial. The aim was to investigate 
Teduglutide [Gly] GLP-2 (GattexTM, NPS Pharmaceuticals, 
Bedminster, NJ), a DPPIV-resistant analog of GLP-2   lacking 
the N-terminal DPPIV cleavage site, has received orphan 
drug designation for the treatment of SBS from the United 
States Food and Drug Administration (FDA) and the 
  European Medicines Agency. In 2007, NPS Pharmaceuticals 
granted Nycomed the rights to teduglutide outside of North 
America.
Clinical trials of glucagon-like 
peptide-2 in SBS
The production of GLP-2 occurs in both the small and large 
bowel via the proglucagon-expressing enteroendocrine 
L-cells but is most abundant in the distal ileum. This may 
explain why functional adaptation appears more effective 
when the residual intestine is ileum rather than jejunum. 
Those with end jejunostomy and no colon, who have the 
poorest intestinal adaptation, have a markedly impaired 
postprandial GLP-2 response, presumably caused by a lack of 
functioning L-cells.29 In contrast, SBS patients with preserved 
colon exhibit increased fasting GLP-2 levels with a postpran-
dial profile comparable to that of healthy controls.30 These 
findings, combined with strong evidence of a correlation 
between GLP-2 and intestinal adaptation in animal models,13 
have raised hopes that GLP-2 therapy might be able to pro-
duce clinically meaningful enhancement of intestinal mass 
and function in patients with SBS.
Results of clinical trials so far have been encouraging. In 
initial uncontrolled open label studies of SBS patients, native 
GLP-2 and the long-acting analog teduglutide significantly 
improved intestinal wet-weight absorption by up to 1 L 
per day. This occurred in patients with end jejunostomy as 
well as in patients with a preserved colon, despite the latter 
group having near normal endogenous GLP-2 levels.31,32 The 
effects have been shown to be maintained for up to 2 years 
of treatment but will quickly wear off following treatment 
termination. The effect on energy absorption appears to 
be minor.
A recently published large multinational, random-
ized, placebo-controlled clinical trial of teduglutide in 83 
post-resection SBS patients requiring PN at least three 
times per week for a minimum of 12 months, has also 
reported a   positive outcome. Following a maximum 8-week 
optimization of PN with a 4–8-week stabilization period, 
patients were randomized into a 24-week treatment protocol 
with placebo (n = 16), 0.05 mg/kg/day teduglutide (n = 35) 
or 0.10 mg/kg/day teduglutide (n = 32). The main measure 
of treatment response was a reduction in parenteral   nutrition Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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whether the PN reductions could be maintained for up to 
1 year, as well as evaluate drug safety and tolerability. The 
results have been published in abstract form, and the final 
publication is anticipated.35 Patients previously on active 
treatment were maintained on their dose, and the placebo-
treated patients were randomized to teduglutide 0.05 or 
0.10 mg/kg/day. In the low-dose group, 12/16 (75%) of 
initial responders maintained the PN reduction; ten of these 
had further reductions. In the high-dose group, 6/8 (75%) 
of initial responders maintained the reduction, and two of 
these had a further reduction. Among the initially placebo-
treated subjects, 6/6 (100%) responded to low-dose and 2/7 
(28%) to high-dose teduglutide. Mean absolute (relative) PN 
reductions from weekly baseline volume were 4.5 L (51%, 
low-dose group) and 3.0 L (24%, high-dose group). Four 
actively treated subjects were weaned off parenteral nutrition 
over the 1-year trial period.
Prior to application for FDA licensing of teduglutide 
as a first-in-class treatment for SBS, a further confirmatory 
Phase 3 study (STEPS – Study of Teduglutide in PN-
dependent Short-bowel syndrome) has just been completed. 
This study randomized 86 SBS patients to either 0.05 mg/kg 
of teduglutide Gattex or placebo over a 24-week period. The 
following unpublished data has been extracted from a recent 
NPS Pharmaceuticals press release (January 31, 2011).36 The 
primary efficacy endpoint was defined as the percentage 
of patients who achieved a 20% or greater reduction in 
weekly PN volume at weeks 20 and 24. In an intention-
to-treat analysis, 63% (27/43) of teduglutide-treated patients 
responded compared with 30% (13/43) of placebo-treated 
patients (P = 0.002). Absolute weekly reduction of PN 
volume was also greater in the teduglutide group compared 
with placebo; 4.4 L (baseline of 12.9 L) vs 2.3 L (baseline 
of 13.2 L). Teduglutide was well tolerated with only four 
patients discontinuing the study due to adverse events (one 
teduglutide treated and three placebo treated). The adverse 
events were consistent with the pharmacological effects of 
the drug. More than 97% of the eligible participants opted 
to participate in the STEPS 2 open-label continuation study 
where all participants will receive an additional 24 months 
of teduglutide therapy.
These clinical studies indicate that teduglutide treatment 
can achieve clinically useful reductions of PN requirements 
in SBS patients, considered being stable on optimal 
conventional management.
Metabolic bone disease is highly prevalent in SBS 
patients on long-term PN. A mediating role for GLP-2 in the 
postprandial decrease in bone resorption has been suggested 
because GLP-2 injection reduces bone resorption marker 
s-CTX in healthy postmenopausal women.37 In a small group 
of SBS patients with jejunostomy, 35-day GLP-2 treatment 
decreased bone resorption markers and increased bone mass 
and bone mineral density (BMD).38 However, other studies 
were unable to replicate the beneficial effect of GLP-2 on 
bone BMD in SBS patients.39,40 The clinical role of GLP-2 in 
the treatment of osteoporosis therefore remains uncertain.
Crohn’s disease is a leading cause for adult SBS. 
Accumulating evidence that GLP-2 has anti-inflammatory 
and reparative properties promoted the expansion of GLP-2 
research into inflammatory bowel disease (IBD). Bioactive 
GLP-2 circulating concentrations are elevated in patients 
with active IBD compared with healthy controls, indicating 
an innate adaptive mechanism to the associated IBD intes-
tinal damage.41 A pilot, proof of concept study was carried 
out on patients with moderate to severely active Crohn’s 
disease. This 8-week, randomized, placebo-controlled, 
dose-ranging trial, which recruited 100 patients, suggests 
a dose-dependent benefit in the reduction of the Crohn’s 
Disease Activity Index (CDAI) score. In the highest dose 
group, 55.6% of patients went into remission vs 33.3% of 
the placebo group. No statistical significance was observed, 
however, and further research must determine whether these 
results relate to symptomatic disease control (by decreasing 
diarrhea) or reflect decrease in inflammatory activity and 
improved mucosal healing. The authors acknowledged the 
pilot nature of the study as well as the use of CDAI as the 
primary outcome.42 Further clinical studies with greater 
statistical power and more effective primary endpoints and 
longer trial period are much needed. Nevertheless, this trial 
provided promising data for the use of teduglutide as a novel 
treatment of intestinal diseases associated with compromised 
repair of the intestinal mucosa.
There has been a number of studies looking at rodent 
models of intestinal injury to explore the mechanisms 
of anti-inflammatory actions of GLP-2.18,25,44 One such 
study carried out by Sigalet et al, investigated the effects 
of GLP-2 treatment on rats with trinitrobenzene sulfonic 
acid-induced ileitis or dextran sulfate sodium-induced 
colitis.25 Apart from trophic effects of GLP-2, treatment 
also resulted in significant reduction in inflammatory mark-
ers, interleukin (IL)-1ß, interferon-γ, and tumor necrosis 
factor-α, along with reduction in neutrophil activity. The 
use of a VIP antagonist confirmed that VIP appeared 
to mediate the anti-inflammatory properties of GLP-2. 
Subsequently, Ivory et al confirmed the anti-inflammatory 
actions of GLP-2 via use of IL-10 knockout (IL-10-/-) Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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mouse model. This study showed that GLP-2 altered the 
mucosal response of inflamed intestinal epithelial cells and 
macrophages by activation of the suppressor of cytokine 
signaling-3 pathway, which antagonizes the   IL-6-mediated 
increase in signal transducers and activators of transcription 
3 signaling. The study also confirmed that this immuno-
modulatory effect was IL-10 independent.18 Translation 
studies “from bench to bedside” may allow the clinical use 
of teduglutide as both a trophic and an immunomodulatory/
immunosuppressive therapy in patients with SBS, in 
particular those who develop SBS from complications of 
Crohn’s disease.
Safety consideration
Clinical studies so far report good drug compliance, 
tolerance, and safety of native GLP-2 and teduglutide, with 
no significant increase of serious adverse events. Most 
commonly reported adverse events are abdominal pain, 
bloating, constipation, nausea, injection site erythema, lower 
limb edema, stoma swelling, headache, and nasopharyngitis. 
Caution is suggested in patients with a history of abdominal 
pain and recurrent subacute obstruction. In cardiac failure, 
increased fluid absorption might lead to decompensation 
and fluid overload.
The therapeutic use of GLP-2 may require lifelong admin-
istration. Because of concerns that permanent stimulation of 
epithelial proliferation might initiate or accelerate malignant 
growth, research into the role of GLP-2 in carcinogenesis 
is ongoing. Low level GLP-2R expression has been dem-
onstrated in cancer cell lines and human tumors including 
colonic adenocarcinomas.43,45 GLP-2 also exerts a direct 
proliferative effect on transformed cell lines despite apparent 
lack of a specific receptor.46 Recent in vivo studies in mouse 
cancer models have added to concerns that GLP-2 may play 
a role in both tumor initiation and progression. Mice that 
were pretreated with carcinogen azoxymethane showed 
an increase in number and size of aberrant crypt foci, 
  presumed precursors of tumor development, when they were 
subsequently treated with GLP-2 vs controls treated either 
with saline or the GLP-2R antagonist GLP-2.3–33 Loss of 
mucin production in aberrant crypts (considered an important 
marker of dysplasia) and formation of adenocarcinomas 
were almost exclusively observed in GLP-2-treated mice 
but not in controls.47 In another model, GLP-2 injections 
increased the number and size of colonic adenomas in mice 
pretreated with the carcinogen 1,2-dimethylhydralazine.48 
It has been argued that the effects of GLP-2 are present 
at the early stage of carcinogenesis, with no effect when 
adenomas and microadenomas have already developed, as 
in the APC min/+ mice model.45 The precise implications of 
such studies for the development of colon cancer in humans 
remain incompletely understood. Until a clear safety profile 
for the long-term use of GLP-2 is established, a high level 
of vigilance is required. This should include mandatory 
screening of prospective patients for pre-malignant lesions 
(particularly colonic adenomas).
Conclusion
The ability of GLP-2 to enhance intestinal adaptation has 
been demonstrated in numerous animal models. There is 
now mounting clinical evidence that it can provide a new 
therapeutic strategy in SBS patients in whom it may pave 
the path towards reducing PN dependence. This, in turn, 
may lead to a reduction in PN-related complications as well 
as improving patients quality of life. GLP-2 appears safe 
and well tolerated in the short and medium term. Optimal 
indications, timing, and dose as well as possible gains from 
coadministration with other growth factors will need to be 
studied further, and long-term colonic surveillance studies 
must be considered to abate safety concerns.
Promising results of the ability of GLP-2 to restore 
mucosal integrity and possible immunomodulatory effects 
bade the question of its use in IBD.
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